MiMedx Group (MDXG) Stock Price

MiMedx Group Price

NASDAQ·CLOSED
4.34USD+0.16 (+3.76 %)
Market closed

Over the last 15 years MiMedx Group grew revenue by 51.9% annually, reaching 418.63 M USD. Earnings per share have grown at 17.6% per year over the last 11 years. For MiMedx Group, the net margin of 11.6% is up versus -5.1% a few years ago. The consensus 12-month price target for MiMedx Group is 10.20 USD, about 135.0% above where the stock trades today. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus. The stock trades about 40% above its 52-week low.

MiMedx Group stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of MiMedx Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how MiMedx Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing MiMedx Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

MiMedx Group Stock Price History
DateMiMedx Group Price
8/7/20264.34 USD
8/6/20264.18 USD
8/5/20264.18 USD
8/4/20264.22 USD
8/3/20264.27 USD
7/31/20264.13 USD
7/30/20264.27 USD
7/29/20264.34 USD
7/27/20264.32 USD
7/23/20264.13 USD
7/22/20264.17 USD
7/21/20264.32 USD
7/20/20264.33 USD
7/17/20264.30 USD
7/16/20264.43 USD
7/15/20264.27 USD
7/14/20264.20 USD
7/13/20264.07 USD
7/10/20264.11 USD
7/9/20264.14 USD
7/8/20264.20 USD
7/7/20264.20 USD
7/6/20263.91 USD
7/2/20263.95 USD
7/1/20263.90 USD
6/30/20263.85 USD
6/29/20263.91 USD
6/26/20263.93 USD
6/25/20263.81 USD
6/24/20263.83 USD
6/23/20263.73 USD
6/22/20263.68 USD
6/18/20263.67 USD
6/17/20263.70 USD
6/16/20263.68 USD
6/15/20263.69 USD
6/12/20263.65 USD
6/11/20263.60 USD
6/10/20263.71 USD
6/9/20263.71 USD
6/8/20263.70 USD
6/5/20263.82 USD
6/4/20263.74 USD
6/3/20263.58 USD
6/2/20263.55 USD
6/1/20263.63 USD
5/29/20263.70 USD
5/28/20263.62 USD
5/27/20263.59 USD
5/26/20263.68 USD
5/22/20263.63 USD
5/21/20263.66 USD
5/20/20263.76 USD
5/19/20263.64 USD
5/18/20263.59 USD
5/15/20263.56 USD
5/14/20263.55 USD
5/13/20263.52 USD
5/12/20263.54 USD
5/11/20263.56 USD
5/8/20263.60 USD
5/7/20263.69 USD
5/6/20263.66 USD
5/5/20263.64 USD
5/4/20263.61 USD
5/1/20263.68 USD
4/30/20263.36 USD
4/29/20263.09 USD
4/28/20263.40 USD
4/27/20263.34 USD
4/24/20263.43 USD
4/23/20263.29 USD
4/22/20263.31 USD
4/21/20263.20 USD
4/20/20263.25 USD
4/17/20263.42 USD
4/16/20263.43 USD
4/15/20263.88 USD
4/14/20263.92 USD
4/13/20263.92 USD
4/10/20263.87 USD
4/9/20264.03 USD
4/8/20263.97 USD
4/7/20263.86 USD
4/6/20263.88 USD
4/2/20263.92 USD
4/1/20263.95 USD
3/31/20263.95 USD
3/30/20263.86 USD
3/27/20263.81 USD
3/26/20263.94 USD
3/25/20264.10 USD
3/24/20264.13 USD
3/23/20264.24 USD
3/20/20264.12 USD
3/19/20264.17 USD
3/18/20264.24 USD
3/17/20264.36 USD
3/16/20264.41 USD
3/13/20264.38 USD
3/12/20264.38 USD
3/11/20264.56 USD
3/10/20264.57 USD
3/9/20264.51 USD
3/6/20264.50 USD
3/5/20264.75 USD
3/4/20264.82 USD
3/3/20264.76 USD
3/2/20264.88 USD
2/27/20264.89 USD
2/26/20264.94 USD
2/25/20265.28 USD
2/24/20265.35 USD
2/23/20265.33 USD
2/20/20265.17 USD
2/19/20265.20 USD
2/18/20265.22 USD
2/17/20265.16 USD
2/13/20265.12 USD
2/12/20265.09 USD
2/11/20265.21 USD
2/10/20265.17 USD
2/9/20265.19 USD
2/6/20265.15 USD
2/5/20265.03 USD
2/4/20265.11 USD
2/3/20264.97 USD
2/2/20265.09 USD
1/30/20265.11 USD
1/29/20265.14 USD
1/28/20265.15 USD
1/27/20265.30 USD
1/26/20265.25 USD
1/23/20265.26 USD
1/22/20265.42 USD
1/21/20265.33 USD
1/20/20265.39 USD
1/16/20265.42 USD
1/15/20265.75 USD
1/14/20265.69 USD
1/13/20265.88 USD
1/12/20266.00 USD
1/9/20266.10 USD
1/8/20266.31 USD
1/7/20266.44 USD
1/6/20266.40 USD
1/5/20266.33 USD
1/2/20266.48 USD
12/31/20256.77 USD
12/30/20256.86 USD
12/29/20256.91 USD
12/26/20256.90 USD
12/24/20257.08 USD
12/23/20257.00 USD
12/22/20257.04 USD
12/19/20257.05 USD
12/18/20257.25 USD
12/17/20257.09 USD
12/16/20257.25 USD
12/15/20257.12 USD
12/12/20257.22 USD
12/11/20257.16 USD
12/10/20256.98 USD
12/9/20256.98 USD
12/8/20256.68 USD
12/5/20256.93 USD
12/4/20256.86 USD
12/3/20256.96 USD
12/2/20256.72 USD
12/1/20256.67 USD
11/28/20256.88 USD
11/26/20256.88 USD
11/25/20256.95 USD
11/24/20256.78 USD
11/21/20256.76 USD
11/20/20256.55 USD
11/19/20256.48 USD
11/18/20256.72 USD
11/17/20257.10 USD
11/14/20257.38 USD
11/13/20257.47 USD
11/12/20257.48 USD
11/11/20257.54 USD
11/10/20257.71 USD
11/7/20257.44 USD
11/6/20257.33 USD
11/5/20257.96 USD
11/4/20257.69 USD
11/3/20257.52 USD
10/31/20257.65 USD
10/30/20257.40 USD
10/29/20257.19 USD
10/28/20256.88 USD
10/27/20256.73 USD
10/24/20256.76 USD
10/23/20256.64 USD
10/22/20256.72 USD
10/21/20256.74 USD
10/20/20256.75 USD
10/17/20256.69 USD
10/16/20256.63 USD
10/15/20256.71 USD
10/14/20256.58 USD
10/13/20256.51 USD
10/10/20256.55 USD
10/9/20256.92 USD
10/8/20257.10 USD
10/7/20257.26 USD
10/6/20257.31 USD
10/3/20257.21 USD
10/2/20256.71 USD
10/1/20256.83 USD
9/30/20256.98 USD
9/29/20256.93 USD
9/26/20256.94 USD
9/25/20256.98 USD
9/24/20257.09 USD
9/23/20257.11 USD
9/22/20257.19 USD
9/19/20257.02 USD
9/18/20257.15 USD
9/17/20256.94 USD
9/16/20256.97 USD
9/15/20256.97 USD
9/12/20256.94 USD
9/11/20257.14 USD
9/10/20256.89 USD
9/9/20257.12 USD
9/8/20257.17 USD
9/5/20257.14 USD
9/4/20257.09 USD
9/3/20257.10 USD
9/2/20257.19 USD
8/29/20257.10 USD
8/28/20257.18 USD
8/27/20257.17 USD
8/26/20257.16 USD
8/25/20257.08 USD
8/22/20257.31 USD
8/21/20257.03 USD
8/20/20257.17 USD
8/19/20257.19 USD
8/18/20257.19 USD
8/15/20257.11 USD
8/14/20257.15 USD
8/13/20257.27 USD
8/12/20257.23 USD
8/11/20257.04 USD
Access this data via the Eulerpool API
Get Free API Key

MiMedx Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
321.48 M USD
37.12 M USD
67.44 M USD
Jan 1, 2024
348.88 M USD
58.87 M USD
42.42 M USD
Jan 1, 2025
418.63 M USD
63.89 M USD
48.58 M USD
Jan 1, 2026 (e)
269.43 M USD
19.60 M USD
-8.61 M USD
Jan 1, 2027 (e)
302.87 M USD
22.03 M USD
11.84 M USD
Jan 1, 2028 (e)
340.92 M USD
24.80 M USD
23.76 M USD
Jan 1, 2029 (e)
375.30 M USD
27.30 M USD
29.94 M USD
Jan 1, 2030 (e)
422.50 M USD
30.73 M USD
40.43 M USD

MiMedx Group Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 9, 2026, 8:19 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
187.00245.00321.00359.00359.00248.00242.00267.00321.00348.00418.00269.00302.00340.00375.00422.00
58.4731.0231.0211.84–-30.92-2.4210.3320.228.4120.11-35.6512.2712.5810.2912.53
89.3086.5388.7989.6989.6983.8783.4782.0282.8782.7682.5482.5482.5482.5482.5482.54
167.00212.00285.00322.00322.00208.00202.00219.00266.00288.00345.00222.02249.26280.62309.51348.30
24.00–46.00-3.00-3.00-44.00-7.00-14.0037.0058.0063.0019.0022.0024.0027.0030.00
12.83–14.33-0.84-0.84-17.74-2.89-5.2411.5316.6715.077.067.287.067.207.11
29.0011.0064.00-29.00-29.00-49.00-12.00-30.0067.0042.0048.00-8.0011.0023.0029.0040.00
383.33-62.07481.82-145.31–68.97-75.51150.00-323.33-37.3114.29-116.67-237.50109.0926.0937.93
112.04113.73113.71105.60106.42108.87113.18113.68148.08149.05149.72149.72149.72149.72149.72149.72
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales MiMedx Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue MiMedx Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare MiMedx Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares MiMedx Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against MiMedx Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

MiMedx Group stock margins

The MiMedx Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of MiMedx Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for MiMedx Group.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
83.63 %
-2.91 %
-5.08 %
Jan 1, 2022
81.96 %
-5.50 %
-11.27 %
Jan 1, 2023
83.01 %
11.55 %
20.98 %
Jan 1, 2024
82.78 %
16.87 %
12.16 %
Jan 1, 2025
82.56 %
15.26 %
11.60 %
Jan 1, 2026 (e)
82.56 %
7.27 %
-3.20 %
Jan 1, 2027 (e)
82.56 %
7.27 %
3.91 %
Jan 1, 2028 (e)
82.56 %
7.27 %
6.97 %

MiMedx Group Stock Revenue, EBIT, Earnings per Share

The MiMedx Group earnings per share therefore indicates how much revenue MiMedx Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
2.14 USD
-0.06 USD
-0.11 USD
Jan 1, 2022
2.36 USD
-0.13 USD
-0.27 USD
Jan 1, 2023
2.17 USD
0.25 USD
0.46 USD
Jan 1, 2024
2.34 USD
0.39 USD
0.28 USD
Jan 1, 2025
2.80 USD
0.43 USD
0.32 USD
Jan 1, 2026 (e)
1.80 USD
0.13 USD
-0.06 USD
Jan 1, 2027 (e)
2.02 USD
0.15 USD
0.08 USD
Jan 1, 2028 (e)
2.28 USD
0.17 USD
0.16 USD

MiMedx Group business model & stock analysis

MiMedx Group Inc is a biopharmaceutical company based in Marietta, Georgia that focuses on the development and marketing of tissue replacement products for chronic wounds. The company was founded in 2008 and has since experienced remarkable growth. History MiMedx was founded by Parker H. "Pete" Petit and John Daniel "Dan" Hannaford III. The company was originally established as SpineMedica Inc., which focused on manufacturing medical devices for spinal treatment. In 2010, the company changed its name to MiMedx Group Inc. and expanded its business activities into the field of regenerative medicine. In 2012, the company launched its first tissue replacement product line, EpiFix, an allogeneic epithelial cell matrix for the treatment of chronic wounds. Since then, the company has expanded its product portfolio through the development and marketing of additional tissue replacement products such as AmnioFix and EpiCord. Business Model MiMedx has a unique business model based on the distribution of tissue replacement products for chronic wounds. The company's products are manufactured and marketed through its subsidiaries MiMedx Biologics and Stability Biologics. MiMedx's business model is based on the concepts of allograft and amniotomy technology. This involves the production of products derived from placenta and umbilical cord that contain a variety of growth factors and bioactive molecules that can aid in the healing of chronic wounds. MiMedx has a strong presence in the US market and works closely with hospitals, clinics, physicians, and insurance companies to provide access to its products. Divisions MiMedx Group offers a variety of products targeting the treatment of chronic wounds. Here are some of the key divisions of the company: 1. EpiFix EpiFix is an allograft product line derived from human placental tissue. It contains a natural matrix of epithelial cells that can aid in the regeneration of skin tissue. EpiFix is used for the treatment of chronic wounds such as venous ulcers and diabetic foot ulcers. 2. AmnioFix AmnioFix is a product line derived from human umbilical cord fluid and placental tissue. It contains a mixture of growth factors and molecules that can be used in tissue and bone healing. AmnioFix is used for the treatment of chronic wounds, tendon injuries, and bone fractures. 3. EpiCord EpiCord is a product line derived from human umbilical cord tissue. It contains a natural matrix of tissues that can aid in the restoration of skin tissue. EpiCord is used for the treatment of chronic wounds, tendon injuries, and bone fractures. Products MiMedx takes pride in its range of tissue replacement products for the treatment of chronic wounds. Here are some of the key products offered by the company: 1. EpiFix VLU EpiFix VLU is a product line specifically designed for the treatment of venous ulcers. It is available in various sizes and provides a natural matrix of epithelial cells that can aid in the regeneration of skin tissue. 2. AmnioFix Injectable AmnioFix Injectable is an injectable tissue replacement product derived from human umbilical cord cells. It contains a mixture of growth factors and molecules that can aid in tissue and bone healing. 3. EpiCord EpiCord is a tissue replacement product derived from human umbilical cord tissue. It contains a natural matrix of tissues that can aid in the regeneration of skin tissue and bone. Summary Overall, MiMedx is an emerging biotechnology company that specializes in the development and marketing of tissue replacement products for chronic wounds. The company has achieved strong growth thanks to its innovative products and unique business model. With its strong presence in the US market and its focus on expanding into growing markets such as Asia and Europe, MiMedx has the potential to become a key player in the regenerative medicine industry.

MiMedx Group SWOT Analysis

Strengths

MiMedx Group Inc has several key strengths that contribute to its success in the market. Firstly, the company demonstrates strong financial performance with consistent revenue growth and healthy profitability ratios. This allows MiMedx to invest in innovation and expand its product offerings. Furthermore, the company benefits from a robust research and development department, enabling it to develop high-quality medical products and stay ahead of competitors. MiMedx also enjoys a strong brand reputation and a loyal customer base due to its focus on delivering reliable and effective healthcare solutions.

Weaknesses

Despite its strengths, MiMedx Group Inc faces certain weaknesses that could hinder its growth. Firstly, the company relies heavily on a few key customers, which poses a risk of significant revenue loss if any customer decides to switch suppliers. Additionally, the company has faced legal issues and regulatory scrutiny in the past, which have created negative publicity and damaged its reputation. Lastly, MiMedx operates in a highly competitive industry, facing intense competition from both established players and new entrants, which can impact its market share.

Opportunities

MiMedx Group Inc has several opportunities to capitalize on in the market. Firstly, the increasing global demand for regenerative medicine and tissue-engineered products presents a significant growth opportunity for the company. MiMedx can leverage its expertise and expand its product portfolio to tap into this growing market. Additionally, partnerships and collaborations with healthcare providers and research institutions can help MiMedx gain access to new markets and increase its customer base. Furthermore, technological advancements in the healthcare industry provide opportunities for MiMedx to develop innovative solutions and gain a competitive edge.

Threats

MiMedx Group Inc faces certain threats that could potentially impede its growth and profitability. Firstly, changes in healthcare policies and regulations can affect the reimbursement rates for medical products, impacting MiMedx's revenue. Additionally, the company operates in a highly regulated industry, and any non-compliance could lead to legal penalties and damage its reputation. Moreover, the possibility of new entrants and technological disruptions poses a threat to MiMedx's market position. Lastly, the company is exposed to fluctuations in raw material prices, which can impact its manufacturing costs and profitability.

MiMedx Group Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

MiMedx Group Employees
Details
Date
MiMedx Group Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

MiMedx Group Segments

MiMedx Group Revenue by Segment (1/3)

  • 3 Years

  • 5 Years

  • Max

Wound
Advanced Wound Care
Hospital
Wound Care
Surgical
Private Office
Surgical, Sports Medicine & Orthopedics (SSO)
Other
Details
Date
Wound
Advanced Wound Care
Hospital
Wound Care
Surgical
Private Office
Surgical, Sports Medicine & Orthopedics (SSO)
Other
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
183.98 M USD
0.00 USD
0.00 USD
61.03 M USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
265.20 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
259,000.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
187.00 M USD
0.00 USD
0.00 USD
95.79 M USD
0.00 USD
38.69 M USD
Jan 1, 2024
0.00 USD
0.00 USD
187.44 M USD
0.00 USD
0.00 USD
112.39 M USD
0.00 USD
49.05 M USD
Jan 1, 2025
276.33 M USD
0.00 USD
0.00 USD
0.00 USD
142.30 M USD
0.00 USD
0.00 USD
0.00 USD

MiMedx Group Revenue by Segment (2/3)

  • 3 Years

  • Max

Wound
Surgical
Cord
Section 351
Details
Date
Wound
Surgical
Cord
Section 351
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
23.60 M USD
17.61 M USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
2.38 M USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
231.00 M USD
117.88 M USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD

MiMedx Group Revenue by Segment (3/3)

  • 3 Years

  • Max

Advanced Wound Care
Hospital
Private Office
Other
Details
Date
Advanced Wound Care
Hospital
Private Office
Other
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
240.02 M USD
0.00 USD
0.00 USD
988,000.00 USD
Jan 1, 2022
0.00 USD
163.21 M USD
77.16 M USD
27.48 M USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD

MiMedx Group Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

MiMedx Group historical P/E ratio, EBIT multiple, and P/S ratio

MiMedx Group annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

MiMedx Group shares outstanding

The number of shares of MiMedx Group was 149.72 M in 2025. This indicates how many shares MiMedx Group is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
113.18 M Stocks
Jan 1, 2022
113.68 M Stocks
Jan 1, 2023
148.08 M Stocks
Jan 1, 2024
149.05 M Stocks
Jan 1, 2025
149.72 M Stocks
Jan 1, 2026 (e)
149.72 M Stocks
Jan 1, 2027 (e)
149.72 M Stocks
Jan 1, 2028 (e)
149.72 M Stocks

MiMedx Group stock splits

In MiMedx Group's history, there have been no stock splits.

Current MiMedx Group forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
90.91 % (10)
Hold
9.09 % (1)
Sell
0.00 % (0)
12M Price Target
10.20
Last Price
4.34
Currency
USD
12M Return Potential
135.02 %
LTM Return
0 %

MiMedx Group Analyst Rating Actions

DateFirmActionRatingReliability
4/30/2026
Citizens
Citizens
MaintainedMarket Outperform–
4/20/2026
Citizens
Citizens
MaintainedMarket Outperform–
4/17/2026
Craig-Hallum
Craig-Hallum
MaintainedBuy–
2/17/2026
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44
1/20/2026
Lake Street
Lake Street
MaintainedBuy–
12/17/2025
Mizuho
Mizuho
MaintainedOutperform31
7/31/2025
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44
7/15/2025
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44
2/27/2025
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44
8/1/2024
Craig-Hallum
Craig-Hallum
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

MiMedx Group Earnings Calls

2025

MiMedx Group Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/4/2026-0.05USD-64.73 MUSD-2026 Q2
5/5/2026-0.02USD-67.08 MUSD-2026 Q1
3/4/20260.07USD-109.07 MUSD-2025 Q4
4/30/20240.04USD-81.40 MUSD-2024 Q1
2/26/20240.07USD-86.75 MUSD-2023 Q4
7/31/2023-0.05USD-61.51 MUSD-2023 Q2
5/1/2023-0.12USD-52.37 MUSD-2023 Q1
2/27/2023-0.04USD-75.65 MUSD-2022 Q4
11/2/2022-0.08USD-67.73 MUSD-2022 Q3
8/2/2022-0.06USD-66.04 MUSD-2022 Q2

EESG©

Eulerpool ESG Scorecard© for the MiMedx Group stock

94/100
99
Environment
99
Social
83
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees57
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees9
Hispano/Latino Management share—
Percentage of Black employees26
Black Management Share—
Percentage of white employees57
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

MiMedx Group shareholder structure

% Name
18.83142%
EW Healthcare Partners
EW Healthcare Partners
5.87314%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
4.78211%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
4.11648%
Trigran Investments, Inc.
Trigran Investments, Inc.
2.54721%
State Street Investment Management (US)
State Street Investment Management (US)
2.02996%
First Light Asset Management, LLC
First Light Asset Management, LLC
...

MiMedx Group Beneficial Ownership Filings (SEC 13D/G)

Free Float
80.9%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
16.90%
R. Scott Barry
R. Scott Barry
SEC ↗
16.90%
Ronald Eastman
Ronald Eastman
SEC ↗
16.90%
Petri Vainio
Petri Vainio
SEC ↗
16.90%
Martin P. Sutter
Martin P. Sutter
SEC ↗
16.90%
Falcon Fund 2 Holding Company, L.P.
Falcon Fund 2 Holding Company, L.P.
SEC ↗
16.90%
2-UGP,
2-UGP,
SEC ↗
11.30%
Okumus Opportunistic Value Fund, Ltd.
Okumus Opportunistic Value Fund, Ltd.
SEC ↗
11.30%
Okumus Fund Management Ltd.
Okumus Fund Management Ltd.
SEC ↗
11.30%
Ahmet H. Okumus
Ahmet H. Okumus
SEC ↗
9.80%
Matthew J. Miller, individually and as co-trustee of the Veritas Trust
Matthew J. Miller, individually and as co-trustee of the Veritas Trust
SEC ↗

MiMedx Group Executives and Management Board

14 members · avg. age 64 · 36 % women

KM

Ms. Kimberly Maersk-Moller (58)

Chief Commercial Officer

3.99 M USD

Management

WH

Mr. William Hulse (51)

Chief Administrative Officer, General Counsel

2.40 M USD
DR

Mr. Douglas Rice (59)

Chief Financial Officer

2.39 M USD
RW

Ms. Ricci Whitlow (57)

Executive Vice President, Chief Operating Officer

2.29 M USD
JC

Mr. Joseph Capper (61)

Chief Executive Officer, Director · since 2023

1.39 M USD
MN

Mr. Matt Notarianni

Head of Investor Relations · since 2023

–

Board of Directors

MW

Dr. M. Kathleen Behrens Wilsey (72)

Independent Chairman of the Board

301,874.00 USD
DP

Ms. Dorothy Puhy (73)

Independent Director

242,388.00 USD
TO

Ms. Tiffany Olson (65)

Independent Director

241,554.00 USD
KN

Mr. K. Todd Newton (62)

Independent Director · since 2019

235,874.00 USD
JB

Mr. James Bierman (72)

Independent Director

234,374.00 USD
CL

Dr. Cato Laurencin (66)

Independent Director

232,499.00 USD

MiMedx Group Supply Chain

Frequently asked questions about MiMedx Group

MiMedx Group Inc. operates as a regenerative medicine company, focused on developing and commercializing therapeutic biologics utilizing human placental tissues. The company's business model revolves around the research, development, manufacturing, and distribution of innovative biomaterial solutions for various therapeutic areas. MiMedx Group Inc. harnesses the regenerative properties of human placental tissues to create and provide safe and effective biologic products for wound care, orthopedic, surgical, and sports medicine applications. By leveraging advanced biotechnology, MiMedx aims to improve patient outcomes and enhance the natural healing process. Through its comprehensive and innovative business model, MiMedx Group Inc. strives to make a positive impact in the field of regenerative medicine.

MiMedx Group Inc is primarily active in the biotechnology and healthcare industries.

The main competitors of MiMedx Group Inc in the market include Organogenesis Holdings Inc, Osiris Therapeutics Inc, and Kerecis Limited.

MiMedx Group Inc is a biopharmaceutical company specializing in regenerative medicine. Founded in 2008, MiMedx focuses on developing and commercializing innovative technologies for tissue repair and healing. The company's portfolio includes products derived from human placental tissue, such as AmnioFix and EpiFix, which have shown great potential in treating various chronic and acute wounds. MiMedx Group Inc has made significant strides in the field of regenerative medicine, earning a reputation for its dedication to patient healing and improving quality of life. With a strong focus on research and development, MiMedx remains committed to advancing tissue regeneration and expanding its product offerings.

MiMedx Group Inc, a leading biopharmaceutical company, has achieved several significant milestones. The company successfully received FDA approval for its flagship product, EpiFix, a revolutionary wound healing therapy. This milestone marked a breakthrough in the treatment of chronic wounds and positioned MiMedx as an industry leader. Additionally, MiMedx reached a major milestone when it expanded its product portfolio, launching AmnioFix, a promising regenerative medicine product. The company's commitment to innovation and extensive clinical research has allowed it to achieve remarkable advancements in the field of wound care, enhancing patients' quality of life and solidifying MiMedx's position as an industry frontrunner.

MiMedx Group Inc is primarily present in the United States.

MiMedx Group Inc represents values of innovation, integrity, and patient-centered care. As a leading biopharmaceutical company, MiMedx is dedicated to developing and commercializing regenerative therapies for various medical conditions. Their corporate philosophy revolves around advancing patient outcomes and improving quality of life through their cutting-edge products and solutions. With a focus on research, clinical excellence, and collaboration, MiMedx aims to redefine the standard of care in the industry. By prioritizing patient needs and employing ethical business practices, MiMedx Group Inc reflects their commitment to delivering transformative healthcare solutions.

Analysts currently set an average price target of 9.86 USD for the MiMedx Group stock (median: 10.20 USD), implying +127.2 % versus the latest price. The consensus is based on 11 analyst ratings.

MiMedx Group Analyst Price Targets 2026

12 analysts currently rate the MiMedx Group stock: 11 recommend buying, 1 holding and 0 selling. For 2026, analysts expect MiMedx Group to generate revenue of 269.43 M USD and earnings per share of -0.06 USD.

MiMedx Group Analyst Price Targets 2026

Converted at the current exchange rate, the MiMedx Group share trades at 3.76 EUR (4.34 USD).

The MiMedx Group share (MDXG) is listed on 2 stock exchanges, including: NASDAQ (MDXG), SIX (Zürich) (MXE.SW).

MiMedx Group Inc is a leading provider in the field of tissue regeneration. The company offers various products that contribute to restoring and healing damaged or injured tissue. The company operates in multiple segments and offers its customers a wide range of products and services. The company's main segment is tissue regeneration. Here, MiMedx offers a wide range of products for the treatment of wounds, trauma, burns, and other injuries. Tissue regeneration is an important area of medicine as it can help accelerate the healing of injuries and reduce the risk of complications. Another important segment of the company is biotechnology. MiMedx produces biodegradable materials and biomaterials that can be used for tissue regeneration. Biotechnology is an emerging field in medicine as it reduces the use of synthetic materials and can improve the healing of tissue damage. In the wound care segment, MiMedx offers a wide range of products for the treatment of various types of wounds. This includes ointments, dressings, and special wound dressings that contribute to the support of healing. Another important area is ophthalmology. MiMedx offers products for the treatment of eye diseases. This includes ointments, eye drops, and special contact lenses that contribute to the support of healing. MiMedx's products are used worldwide and utilized by doctors and clinics. The company works closely with medical and research institutions to constantly improve its products and ensure their effectiveness and safety. As a company, MiMedx focuses on innovation and progress. The company is constantly searching for new products and technologies to provide its customers with the best products and services. MiMedx's business model is based on the sale of medical products and services. The company works closely with medical and research institutions to constantly improve its products and ensure their effectiveness and safety. Overall, MiMedx offers its customers a wide range of products and services that can contribute to tissue regeneration and healing of injuries. The company is constantly striving to improve its products and adapt to the needs of its customers. Answer: MiMedx Group Inc is a leading provider in the field of tissue regeneration, offering a wide range of products and services for the restoration and healing of damaged or injured tissue in various medical segments.

The expected revenue of MiMedx Group is 269.43 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of MiMedx Group is -8.61 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of MiMedx Group is currently -75.48. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the MiMedx Group stock.

The price-to-sales ratio (P/S) of MiMedx Group is currently 2.41. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the MiMedx Group stock.

The Eulerpool Quality Score for MiMedx Group is 5/10.

The ISIN of MiMedx Group is US6024961012. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of MiMedx Group is A0MS6X. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of MiMedx Group is MDXG. The ticker symbol is used to trade MiMedx Group shares on the stock exchange.

MiMedx Group paid dividends every year for the past 0 years.

MiMedx Group is assigned to the 'Health' sector.

The dividends of MiMedx Group are distributed in USD.

All fundamentals and in-depth analysis of MiMedx Group

Our stock analysis for MiMedx Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MiMedx Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

MiMedx Group Stock
MiMedx Group Revenue→
MiMedx Group Stock
MiMedx Group Net Income→
MiMedx Group Stock
MiMedx Group P/E→
MiMedx Group Stock
MiMedx Group P/S→
MiMedx Group Stock
MiMedx Group EBIT→
MiMedx Group Stock
MiMedx Group Dividend→
MiMedx Group Stock
MiMedx Group Directors Dealings→
MiMedx Group Stock
MiMedx Group Stocks→
MiMedx Group Stock
MiMedx Group Market capitalization→
MiMedx Group Stock
MiMedx Group Debt→
MiMedx Group Stock
MiMedx Group Liabilities→
MiMedx Group Stock
MiMedx Group Equity→
MiMedx Group Stock
MiMedx Group AAQS→
MiMedx Group Stock
MiMedx Group Employees→
MiMedx Group Stock
MiMedx Group ROE→
MiMedx Group Stock
MiMedx Group ROA→
MiMedx Group Stock
MiMedx Group ROCE→
MiMedx Group Stock
MiMedx Group News→
MiMedx Group Stock
MiMedx Group Analyst Price Targets→

Health Stocks

Minapharm Pharmaceuticals SAEMillennium Pharmacon International Tbk PTMindMaze Therapeutics HoldingMilestone ScientificMindWalk HoldingsMilestone PharmaceuticalsMineralys TherapeuticsMiddle East Pharmaceutical Industries Company SJSCMinerva NeurosciencesMiddle East Healthcare Company SJSCMinerva SurgicalMicroTech Medical (Hangzhou) CoAll Stocks A–Z →